Terms: = Prostate cancer AND FHIT, P49789, FRA3B, AP3Aase, ENSG00000189283, 2272
23 results:
1. Clinical Effect of Fuzheng Guben Decoction in the Treatment of Localized prostate cancer and Its Influence on Immune Function under Continuous Nursing Intervention.
Zhou Y; Liu L; Gao L
Contrast Media Mol Imaging; 2022; 2022():3472722. PubMed ID: 36185576
[TBL] [Abstract] [Full Text] [Related]
2. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
Chen W; Lee Z; Awadallah A; Zhou L; Xin W
Diagn Pathol; 2020 Jul; 15(1):92. PubMed ID: 32703222
[TBL] [Abstract] [Full Text] [Related]
3. Upregulation of miR-130b Contributes to Risk of Poor Prognosis and Racial Disparity in African-American prostate cancer.
Hashimoto Y; Shiina M; Dasgupta P; Kulkarni P; Kato T; Wong RK; Tanaka Y; Shahryari V; Maekawa S; Yamamura S; Saini S; Deng G; Tabatabai ZL; Majid S; Dahiya R
Cancer Prev Res (Phila); 2019 Sep; 12(9):585-598. PubMed ID: 31266828
[TBL] [Abstract] [Full Text] [Related]
4. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells.
Watson DG; Tonelli F; Alossaimi M; Williamson L; Chan E; Gorshkova I; Berdyshev E; Bittman R; Pyne NJ; Pyne S
Cell Signal; 2013 Apr; 25(4):1011-7. PubMed ID: 23314175
[TBL] [Abstract] [Full Text] [Related]
5. [Expressions of fhit and PTEN and their significance in prostate cancer].
Xiao Q; Gu XW; Jiang JX; Wang CM; Xu Q
Zhonghua Nan Ke Xue; 2011 Feb; 17(2):136-9. PubMed ID: 21404710
[TBL] [Abstract] [Full Text] [Related]
6. Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer.
Kattan MW; Yu C; Salomon L; Vora K; Touijer K; Guillonneau B
Urology; 2011 Feb; 77(2):396-401. PubMed ID: 20970840
[TBL] [Abstract] [Full Text] [Related]
7. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells.
Mishra DK; Chen Z; Wu Y; Sarkissyan M; Koeffler HP; Vadgama JV
Mol Cancer Ther; 2010 Jan; 9(1):33-45. PubMed ID: 20053773
[TBL] [Abstract] [Full Text] [Related]
8. Novel biomarkers for prostate cancer including noncoding transcripts.
Romanuik TL; Ueda T; Le N; Haile S; Yong TM; Thomson T; Vessella RL; Sadar MD
Am J Pathol; 2009 Dec; 175(6):2264-76. PubMed ID: 19893039
[TBL] [Abstract] [Full Text] [Related]
9. Strong signature of natural selection within an fhit intron implicated in prostate cancer risk.
Ding Y; Larson G; Rivas G; Lundberg C; Geller L; Ouyang C; Weitzel J; Archambeau J; Slater J; Daly MB; Benson AB; Kirkwood JM; O'Dwyer PJ; Sutphen R; Stewart JA; Johnson D; Nordborg M; Krontiris TG
PLoS One; 2008; 3(10):e3533. PubMed ID: 18953408
[TBL] [Abstract] [Full Text] [Related]
10. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.
Murphy TM; Perry AS; Lawler M
Endocr Relat Cancer; 2008 Mar; 15(1):11-25. PubMed ID: 18310272
[TBL] [Abstract] [Full Text] [Related]
11. Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure.
Brenot-Rossi I; Rossi D; Esterni B; Brunelle S; Chuto G; Bastide C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):32-8. PubMed ID: 17828535
[TBL] [Abstract] [Full Text] [Related]
12. Association between germline variation in the fhit gene and prostate cancer in Caucasians and African Americans.
Levin AM; Ray AM; Zuhlke KA; Douglas JA; Cooney KA
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1294-7. PubMed ID: 17548701
[TBL] [Abstract] [Full Text] [Related]
13. Common chromosomal fragile site FRA16D mutation in cancer cells.
Finnis M; Dayan S; Hobson L; Chenevix-Trench G; Friend K; Ried K; Venter D; Woollatt E; Baker E; Richards RI
Hum Mol Genet; 2005 May; 14(10):1341-9. PubMed ID: 15814586
[TBL] [Abstract] [Full Text] [Related]
14. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing fhit.
Larson GP; Ding Y; Cheng LS; Lundberg C; Gagalang V; Rivas G; Geller L; Weitzel J; MacDonald D; Archambeau J; Slater J; Neuberg D; Daly MB; Angel I; Benson AB; Smith K; Kirkwood JM; O'Dwyer PJ; Raskay B; Sutphen R; Drew R; Stewart JA; Werndli J; Johnson D; Ruckdeschel JC; Elston RC; Krontiris TG
Cancer Res; 2005 Feb; 65(3):805-14. PubMed ID: 15705877
[TBL] [Abstract] [Full Text] [Related]
15. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract] [Full Text] [Related]
16. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract] [Full Text] [Related]
17. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Minna JD; McConnell J; Frenkel EP; Gazdar AF
Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671
[TBL] [Abstract] [Full Text] [Related]
18. Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model.
Guo Z; Johansson SL; Rhim JS; Vishwanatha JK
Prostate; 2000 May; 43(2):101-10. PubMed ID: 10754525
[TBL] [Abstract] [Full Text] [Related]
19. prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
[TBL] [Abstract] [Full Text] [Related]
20. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors.
Kochera M; Depinet TW; Pretlow TP; Giaconia JM; Edgehouse NL; Pretlow TG; Schwartz S
Prostate; 1999 Sep; 41(1):7-11. PubMed ID: 10440870
[TBL] [Abstract] [Full Text] [Related]
[Next]
